The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:https://doi.org/10.1176/ps.38.8.835

The recently discovered high prevalence of the anxiety disorders, as well as studies demonstrating their strong association with psychophysiologic symptoms, will probably increase referrals for these disorders to psychiatric clinicians. The authors review developments since 1983 in the psychopharmacologic and psychologic-behavioral treatment of the anxiety disorders. They find a growing body of empirical evidence that a variety of pharmacologic and cognitively oriented behavioral therapies are effective treatments. Less evidence is available for the utility of psychodynamic therapies, although recent studies provide some support. The authors believe that as a general rule, treatment of the more severe anxiety symptoms should always include pharmacotherapy.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.